US Patent Issued to Ultragenyx Pharmaceutical on Nov. 18 for "Gene therapy for treating propionic acidemia" (Massachusetts, Ohio, California Inventors)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,472,268, issued on Nov. 18, was assigned to Ultragenyx Pharmaceutical Inc. (Novato, Calif.).

"Gene therapy for treating propionic acidemia" was invented by Matthew Scott Fuller (Millis, Mass.), Samuel Wadsworth (Shrewsbury, Mass.), Kelly Reed Clark (Westerville, Ohio), Sean Christopher Daugherty (Petaluma, Calif.) and Stewart Craig (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "This present disclosure provides adeno-associated viral vectors, recombinant adeno-associated virus (rAAV), and methods of their use in gene therapy for treating propionic acidemia (PA). Also provided are pharmaceutical compositions comprising a recombinant aden...